NASDAQ · TLSA
Healthcare · Biotechnology
$1.11
Down-$0.01 (-0.90%)
Updated Oct 7, 2026, 10:54 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TLSA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
TLSA closed at $1.11 after 21 trading sessions, up 12.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.08 | $1.135 | $1.05 | $1.11 | 634.19K |
| Oct 5, 2026 | $1.12 | $1.14 | $1.07 | $1.07 | 274.64K |
| Oct 2, 2026 | $1.16 | $1.20 | $1.10 | $1.12 | 436.82K |
| Oct 1, 2026 | $1.11 | $1.19 | $1.09 | $1.14 | 697.72K |
| Sep 30, 2026 | $0.995 | $1.14 | $0.9667 | $1.11 | 1.52M |
| Sep 29, 2026 | $0.981 | $1.0296 | $0.9417 | $0.9537 | 511.42K |
| Sep 28, 2026 | $1.01 | $1.05 | $0.96 | $0.9805 | 389.12K |
| Sep 25, 2026 | $1.03 | $1.08 | $1.00 | $1.01 | 382.73K |
| Sep 24, 2026 | $1.10 | $1.11 | $1.00 | $1.04 | 707.38K |
| Sep 23, 2026 | $0.89 | $1.06 | $0.8862 | $1.05 | 1.58M |
| Sep 22, 2026 | $0.89 | $0.8932 | $0.8702 | $0.8899 | 624.15K |
| Sep 21, 2026 | $0.94 | $0.9499 | $0.90 | $0.9046 | 534.94K |
| Sep 18, 2026 | $0.97 | $0.98 | $0.9056 | $0.9056 | 414.83K |
| Sep 17, 2026 | $0.85 | $1.01 | $0.846 | $0.97 | 1.75M |
| Sep 16, 2026 | $0.8482 | $0.88 | $0.7615 | $0.7701 | 852.66K |
| Sep 15, 2026 | $0.89 | $0.89 | $0.81 | $0.852 | 659.46K |
| Sep 14, 2026 | $0.96 | $0.98 | $0.8822 | $0.8902 | 565.01K |
| Sep 11, 2026 | $0.978 | $0.996 | $0.9343 | $0.96 | 277.71K |
| Sep 10, 2026 | $0.9599 | $0.9797 | $0.95 | $0.964 | 194.82K |
| Sep 9, 2026 | $0.9904 | $1.0108 | $0.953 | $0.9767 | 245.62K |
| Sep 8, 2026 | $1.02 | $1.03 | $0.9601 | $0.9897 | 908.22K |
The latest Smart Investors Daily articles mentioning TLSA.
Company
Market Activity
Research & News
TLSA research
Company profile and research snapshot.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | BTIG | Buy | — |
| Sep 3, 2026 | BTIG | Buy | — |
| Jun 13, 2022 | ThinkEquity | Buy | — |
| Apr 12, 2021 | Zacks Investment Research | Not Rated | — |
| Sep 21, 2020 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 30, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies. MSA is a rapidly progressive...
Yahoo · Sep 30, 2026
US futures edge lower ahead of inflation data. Gold rises Brent crude futures climb 1:00 pm BST: US markets remain cautious US stock futures were slightly lower, pointing to a subdued Wall Street open, with Dow futures down 43p, or 0.08%, at 51,659, S&P 500 futures...
Yahoo · Sep 30, 2026
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy (MSA). MSA i
Yahoo · Sep 29, 2026
Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce an important milestone in the company’s neuroimmunology pipeline, with the first three participants receiving their initial doses of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial. The study is evaluating intranasal foralumab as a potential treatment for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that damages nerve cells responsible for controlling voluntary muscle movement. The BANYAN trial is sponsored by Tiziana Life Sciences and co-funded by the ALS Association through its Hoffman ALS Clinical Trial Awards Program. Elrifi said the dosing of the first participants represents an important step in advancing the clinical development of foralumab and supports Tiziana’s broader strategy of investigating therapies designed to target neuroinflammatory mechanisms that may play a role in neurological diseases. The Phase 2a study is initially being conducted at the Sean M. Healey & AMG Center for ALS at Mass General Brigham in Boston. The company expects the trial to expand to additional clinical sites, including Northwestern Medicine’s Les Turner ALS Center in Chicago, the University of Minnesota in Minneapolis and Nova Southeastern University in Florida. BANYAN is expected to enroll 44 people with early-stage ALS who meet specific clinical and biomarker criteria. Participants must have experienced symptom onset within the previous 24 months, have a slow vital capacity of at least 65%, and demonstrate elevated levels of neurofilament light chain (NfL) of 40 pg/mL or greater. Participants will be randomized in a 3-to-1 ratio to receive either intranasal foralumab or placebo during a 12-week controlled treatment period. This will be followed by a 12-week extension phase during which all participants will receive active treatment. The primary objective of the study is to assess the safety and tolerability of intranasal foralumab in people with ALS. Investigators will also evaluate a series of secondary and exploratory endpoints intended to provide additional information on the treatment’s biological activity and its potential effects on disease-related biomarkers. As enrollment and treatment continue, Tiziana expects the BANYAN study to generate additional data on the safety profile and immunological activity of intranasal foralumab in ALS patients. The company says the research could also contribute to a broader understanding of how modulation of the immune system may influence processes associated with neurodegenerative disease. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #ALS #AmyotrophicLateralSclerosis #Biotech #ClinicalTrials #NeurodegenerativeDisease #Neuroimmunology #DrugDevelopment #LifeSciences #HealthcareInnovation #Biotechnology #MedicalResearch #SteveDarling
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TLSA.
No results
No recent SID articles mention TLSA.
